Concepedia

Virangika K. Wimalasena

VK

Statistics

Publications

5

Citations

307

H-Index

5

Active since

2019

Affiliations

Harvard University(Current)

Dana-Farber Cancer Institute

University of California San Diego

Moffitt Cancer Center

University of South Florida

Virangika K. Wimalasena is an author at Harvard University specializing in life sciences, cancer biology, and multiple myeloma therapy.

Publications per year

2019–2022

5

Publications

5

EP300 Selectively Controls the Enhancer Landscape of <i>MYCN</i> -Amplified Neuroblastoma

Adam D. Durbin, Tingjian Wang, Virangika K. Wimalasena et al. · Cancer Discovery · 2021 · 163 citations · Full text

Life Sciences, Cancer Biology, Genetics +17

Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma

Yan Song, Paul M.C. Park, Lei Wu et al. · Leukemia · 2019 · 46 citations

Medicine, Cancer Biology, Oncology +13

Lysine Demethylase 5A Is Required for MYC-Driven Transcription in Multiple Myeloma

Hiroto Ohguchi, Paul M.C. Park, Tingjian Wang et al. · Blood Cancer Discovery · 2021 · 40 citations · Full text

Life Sciences, Genetics, Molecular Biology +17

Development of Dimethylisoxazole-Attached Imidazo[1,2-<i>a</i>]pyridines as Potent and Selective CBP/P300 Inhibitors

Alex Muthengi, Virangika K. Wimalasena, Hailemichael O. Yosief et al. · Journal of Medicinal Chemistry · 2021 · 30 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +11

Colicin E1 opens its hinge to plug TolC

S. Jimmy Budiardjo, Jacqueline J. Stevens, Anna L. Calkins et al. · eLife · 2022 · 28 citations · Full text

Life Sciences, Biology, Microbiology +17

1–5 of 5